Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis?

Journal of Autoimmunity

Volumn 9, Issue 6, 1996, Pages 777-784

  Heresbach, Denis ^a   Alizadeh, Mehdi ^b   Reumaux, Dominique ^c   Colombel, Jean Frédéric ^d   Delamaire, Maryvonne ^e   Danze, Pierre Marie ^d   Gosselin, Michel ^a   Genetet, Bernard ^b   Bretagne, Jean François ^a   Semana, Gilbert ^b  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b Lab Universitaire d'Immunologie   (France)

^c Departement d'H   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e Etablissement de Transfus Sanguine   (France)

Author keywords

HLA class II genotypes; HLA DR2; p ANLA status; ulcerative colitis

Indexed keywords

GRANULOCYTE ANTIBODY; HLA DR ANTIGEN;

ADULT; ARTICLE; FEMALE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HLA SYSTEM; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030460312     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0100     Document Type: Article

References (59)

1. 1. Asakura H., Tsuchiya M., Aiso S., Watanabe M. Kobayashi K., Hibi T., Ando K., Takata H., Sekiguchi S. 1982. Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis. Gastroenterology 82: 413-418
2. 2. Kobayashi K., Atoh M., Konoeda Y., Yagita A., Inoko H., Sekiguchi S. 1990. HLADR, DQ and T cell antigen receptor constant beta genes in Japanese patients with ulcerative colitis. Clin. Exp. Immunol. 80: 400-403
3. 3. Sugimura K., Asakura H., Mizuki N., Inoue M., Hibi T., Yagita A., Tsuji K., Inoko H. 1993. Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. Hum. Immunol. 36: 112-118
4. 4. Futami S., Aoyama N., Tamura T., Honsako Y., Morimoto S., Nakashima T., Ohmoto A., Okano H., Miyamoto H., Sakamoto C., Yasutake K., Amano M., Maeda H., Kubota S., Mitooka H.H., Sakatani N., Nase Y., Kasuga M. 1994. HLA-class II 3-chain position 86: association with susceptibility to ulcerative colitis. Gastroenterology 106: A684 (Abstract)
5. 5. Caruso C., Palmeri P., Oliva L., Orlando A., Cottone M. 1985. HLA antigens in ulcerative colitis: a study in the Sicilian population. Tissue Antigens 25: 47-49
6. 6. Smolen J.S., Gangl A., Polterauer P., Menzel E.J., Mayr W.R. 1982. HLA antigens in inflammatory bowel disease. Gastroenterology 2: 34-38
7. 7. McConnell R.B. 1983. Ulcerative colitis - genetic features. Scand. J. Gastroenterol. 18 (suppl. 88): 14-16
8. 8. Zetterquist H., Broomé U., Einarsson K., Olerup O. 1992. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 33: 942-946
9. 9. Mehal W.S., Lo Y., Wordsworth B.P., Neuberger J.M., Hubscher S.C., Fleming K.A., Chapman R.W. 1994. HLA DR4 is a marker for rapid progression in primary sclerosing cholangitis. Gastroenterology 106: 160-167
10. 10. Burnham W.R., Gelsthorpe K., Langman M.J.S. 1981. HLA-D related antigens in inflammatory bowel disease. In Recent advances in Crohn's disease, Pena A.S., Weterman I.T., Booth C.C., Strober W., eds. The Hague: Martinus Nijhoff, 192-196
11. 11. Cottone M., Brunce M., Taylor C.J., Ting A., Jewell D.P. 1985. Ulcerative colitis and HLA phenotype. Gut 26: 952-954
12. 12. Yang H., Rotter J.I., Toyoda H., Landers C., Tyan D., McElree C.K., Targan S.R. 1993. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J. Clin. Invest. 92: 1080-1084
13. 13. Duerr R.H., Neigut D.A. 1995. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 108: 423-427
14. 14. Farrant J.M., Bunce M., Arlett C., Landers C., Welsh K.I., Toyoda H., Targan S., Jewell D.P. 1994. HLA DR2 is a susceptibility marker for UC in British patients irrespective of ANCA positivity. Gastroenterology 106: A679
15. 15. Masuda F.D., Nakamura Y., Tanaka T., Hayakawa S. 1994. Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am. J. Gastroenterol. 89: 1957-1962
16. 16. Le Berre N., Heresbach D., Kerbaol M., Caulet S., Bretagne J.F., Chaperon J., Gosselin M., Ramée M.P. 1995. Histological discrimination of idiopathic inflammatory bowel disease from other types of colitis. J. Clin. Pathol. 48: 749-753
17. 17. Truelove S.C., Willoughby C.P., Lee E.G., Kettlewell M.A.G.W. 1978. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 2: 1087-1088
18. 18. Wiik A. 1989. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS 97: 12-13
19. 19. Hagen B.C., Andrassy K., Chernok E., Daha M.R., Gaskin G., Gross W., Lesarvre P., Ludermann J., Pusey C.D., Ramussen N., Sawage C.O.S., Simio A., Wuk A., van der Woude F.J. 1993. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. J. Immunol. Meth. 159: 1-16
20. 20. Colonna M., Bresnahan M., Bahram S., Strominger J.L., Spies T. 1992. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc. Natl. Acad. Sci. USA 89: 3932-3936
21. 21. Powis S.H., Tonks S., Mockridge I., Kelly A.P., Bodmer J.G., Trowsdale J. 1993. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics: 376-380
22. 22. Colombel J.F., Danzé P.M., Jacquot S., Loste M.N., Heresbach D., Ategbo S., Kinasi A., Perichon B., Semana G., Cezard J.P. 1995. HLA classe II et maladie de Crohn. Les fréquences génétiques sont-elles différentes chez l'adulte et chez l'enfant? Gastrol. Clin. Biol. 19: A37
23. 23. Hugo J.P., Laurent-Puig P., Gower-Rousseau C., Caillat-Zuckman S., Beaugerie L., Dupas J.L., VanGossum A., Bonait-Pellie C., Cortot A., Thomas A. 1994. Linkage analyses of chromosome A loci, including HLA, in familial aggregations of Crohn's disease. Am. J. Med. Genet. 52: 207-213
24. 24. Nepom C.T. 1990. A unified hypothesis for the complex genetic of HLA association with IDDM. Diabetes 39: 1153-1157
25. 25. Geluk A., Van Meijgaarden K.E., Southwood S., Oseroff C., Drijfhout J.V., de Vries R.R.P., Ottenhoff T.H.M., Sette A. 1994. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J. Immunol. 152: 5742
26. 26. Sidney J., Oseroff C., Southwood S., Wall M., Ishioka G., Koning F. and Sette A. 1992. DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DRB1 alleles. J. Immunol. 8: 2634-2640
27. 27. Chicz R.M., Urban R.G., Gorga J.C., Vignali D.A.A., Lane W.S., Strominger J.L. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178: 27-47
28. 28. Geluk A., van Meijgaarden K.E., Janson A.A.M., Drijfhout J.W., Meloen R.H., de Vries R.R.P., Ottenhoff T.H.M. 1992. Functional analysis of DR1 (DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J. Immunol. 9: 2864-2871
29. 29. Marsh S.G.E., Bodmer J.G. 1995. HLA class II region nucleotide sequences. Tissue Antigens 45: 258-280
30. 30. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364: 33-39
31. 31. Toyoda H., Wang S.J., Yang H.Y., Redford A., Magalong D., Tyan D., McElree C.K., Pressman S.R., Shanahan F., Targan S.R., Rotter J.I. Distinct association of HLA class II genes with inflammatory bowel disease. Gastroenterology 104: 741-748
32. 32. Annese V., Piepoli A., Napolitano G., Perri F., Caruso N., Ciavarella G., Andriulli A. 1995. Are HLA and pANCA markers of genetic heterogeneity in ulcerative colitis? Gastroenterology 108: A311
33. 33. Oudkerk Pool M., Roca M., Reumaux D., Bouma G., Salvador Pena A., Colombel J.F., von Blomberg B.M.E., Meuwissen S.G.M. 1994. The value of pANCA as a serological marker for ulcerative colitis in different European regions. Eur. J. Gastroenterol. Hepatol. 6: 399-403
34. 34. Reumaux D., Colombel J.F., Heresbach D., Duclos B., Chaussade S., Belaiche J., Dupas J.L. Diaz D., Jacquot S., Molic C., Duthilleul P. 1993. Antineutrophil cytoplasmic auto-antibodies in sera from patients after proctocolectomy for ulcerative colitis. Gastroenterology 104: A769
35. 35. Schumacher G., Kollberg B., Sandstedt B., Ljungh A., Nassberger L. 1995. Circulating granulocyte antibodies in first attacks of colitis. Scand. J. Gastroenterol. 30: 157-163
36. 36. Saxon A., Shanahan F., Landers C., Ganz T., Targan S. 1990. A distinct subset of antineutrophil cytoplasmic antibodies associated with IBD. J. Allergy Clin. Immunol. 86: 202-210
37. 37. Colombel J.F., Reumaux D., Dutilleul P., Noel L.H., Gower-Rousseau C., Paris J.C., Cortot A. 1992. Antineutrophil cytoplasmic auto-antibodies in inflammatory bowel disease. Gastroenterol. Clin. Biol. 16: 656-660
38. 38. Cambridge G., Rampton D.S., Stevens T.R.J., McCarthy D.A., Kann M., Leaker B. 1992. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 30: 668-674
39. 39. Reumaux D., Colombel J.F., Delecourt L., Noël L.H., Cortot A., Duthilleul P. 1993. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in patients with ulcerative colitis (UC): influence of disease activity and familial study. Adv. Exp. Med. Biol. 336: 515-518
40. 40. Oudkerk Pool M., Ellerbroek P.M., Ridwan B.U., Goldschmeding R., Von Blonberg B.M.E., Pena A.S., Dolman K.M., Bril H., Dekker W., Nauta J.J., Gans R.O.B., Breed H., Meuwissen S.G.M. 1993. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 34: 45-50
41. 41. Sandborn W.J., Landers C.J., Steiner B.L., Tremaine W.J., Targan S.R. 1994. Unexpectedly high prevalence of antineutrophil cytoplasmic antibody (ANCA) in patients with treatment-resistant, left-sided ulcerative colitis (UC). Gastroenterology 106: A766
42. 42. Vecchi M., Blanchi M.B., Sinico R.A., Radice A., Meucci G., Torgano G., Omodei P., Forzenigo L., Landoni H., Arrigoni H., Pozzi C., de Franchis R. 1994. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion 55: 34-39
43. 43. Mulder A.H.L., Broekroelofs J., Horst G., Limburg P.C., Nelis G.F., Kallenberg C.M.M. 1994. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin. Exp. Immunol. 95: 490-497
44. 44. Broekroelofs J., Mulder A.H.L., Nelis G.F., Westerveld B.D., Tervaert J.W.C., Kallenberg C.G.M. 1994. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity. Dig. Dis. Sci. 39: 545-549
45. 45. Seibold F., Weler P,. Kleim R., Berg P.A., Wiedman K.H. 1992. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 33: 657-662
46. 46. Roth M., Rump J.A., Gross W.L., Peter H.M., Geroh W., Scholmerich J.A. 1991. A new type of antineutrophil antibodies in sera from patients with ulcerative colitis but not Crohn's disease. Gastroenterology 100: A244
47. 47. Sung J.Y., Francis K.L., Lawton J., Leung J.C.K., Liew M.C.T., Leung N.W.Y., Hsu R., Lai K.N. 1994. Anti-neutrophil cytoplasmic antibodies (ANCA) and inflammatory bowel disease in Chinese. Dig. Dis. Sci. 39: 886-892
48. 48. Seibold F., Klein R., Slametschka D., Gregor M., Weber P. 1994. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 107: 532-536
49. 49. Shanahan F., Duerr R.H., Rotter J.I., Yang H., Sutherland L.R., McElree C., Landers C.J., Targan S.R. 1992. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 103: 456-461
50. 50. Yang P., Janerot D., Danielson D., Tysk C., Lindberg E. 1975. P-ANCA in monozygotic twins with inflammatory bowel disease. Gut 36: 887-890
51. 51. Yang H., Rotter J.I. 1994. The genetics of inflammatory bowel disease. In Inflammatory bowel disease from bench to bedside, Targan S.R., Shanahan F., eds. Baltimore: Williams and Wilkins, 32-64
52. 52. Caillat-Zucman S., Bertin F., Timsit J., Boitard C., Assan R., Bach J.F 1993. Protection from insulin-dependent diabetes mellitus is linked to peptide transporter gene. Eur. J. Immunol. 23: 1784-1788
53. 53. Ronningen K.S., Undlien D.E., Ploski R., Maouni N., Konrad R.J., Jensen E., Hornes E., Reijonen H., Colonna M., Monos D.S., Strominger J.L., Thorsby E. 1993. Linkage disequilibrium between TAP2 variants and HLA class II alleles; no primary association between TAP2 variants and insulin-dependent diabetes mellitus. J. Immunol. 23: 1050-1056
54. 54. Van Endert P.M., Liblau R.S., Patel S.D., Fugger L., Lopez T., Pociot F., Nerup J., McDevitt H.O. 1994. Major histocompatibility complex-encoded antigen processing gene polymorphism in IDDM. Diabetes 43: 110-117
55. 55. Moins-Teisserenc H., Semana G., Alizadeh M., Loiseau P., Bobrynina V., Deschamps I. 1995. TAP2 gene polymorphism contributes to genetic susceptibility to multiple sclerosis. Hum. Immunol. 42: 195-202
56. 56. Liblau R., Van Endert P.M., Sandberg-Wollheim M., Patel S.D., Lopez M.T., Land S., Fugger L., McDevitt H.O. 1993. Antigen processing gene polymorphisms in HLA-DR2 multiple sclerosis. Neurology 43: 1192-1197
57. 57. Spies T., Bresnahan M., Bahram S., Arnold D., Blanck G., Mellins E., Pious D., De Mars R. 1990. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 348: 744-747
58. 58. Powis S.J., Deverson E.V., Coadwell W.J., Ciruela A., Huskisson N.S., Smith H., Butcher G.W., Howard J.C. 1992. Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature 357: 211-215
59. 59. Obst R., Armandola E.A., Nijenhuis M., Momburg F., Hammerling G.J. 1995. TAP polymorphism does not influence transport of peptide variants in mice and humans. Eur. J. Immunol. 25: 2170-2176